Showing results (21-30 of 35) with videos related to
Sort By:
Pageof 4
Journal for Immunotherapy of Cancer|August 24, 2019
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignanciesAung Naing, Jeffrey Infante, Sanjay Goel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2022
Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid TumorsJonathan W Goldman, Sarina A Piha-Paul, Brendan Curti, et al.Cancer Journal (Sudbury, Mass.)|January 22, 2014
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United StatesLawrence Flaherty, Omid Hamid, Gerald Linette, et al.Seminars in Oncology|November 16, 2010
Signaling through OX40 enhances antitumor immunityShawn M Jensen, Levi D Maston, Michael J Gough, et al.NPJ Precision Oncology|July 18, 2024
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumabHelen Gogas, Shruthi Ravimohan, Antara Datta, et al.Cancer Immunology, Immunotherapy : CII|October 8, 2016
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinomaAjjai Alva, Gregory A Daniels, Michael K K Wong, et al.Journal of Translational Medicine|May 4, 2012
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"Paolo A Ascierto, Antonio M Grimaldi, Brendan Curti, et al.The New England Journal of Medicine|June 3, 2011
gp100 peptide vaccine and interleukin-2 in patients with advanced melanomaDouglas J Schwartzentruber, David H Lawson, Jon M Richards, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2016
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell CarcinomaToni K Choueiri, Mayer N Fishman, Bernard Escudier, et al.The New England Journal of Medicine|September 22, 2021
Overall Survival Benefit with Tebentafusp in Metastatic Uveal MelanomaPaul Nathan, Jessica C Hassel, Piotr Rutkowski, et al.Pageof 4